The pan-HDAC inhibitors, such as VPA and arginine butyrate, effectively enhanced the sensitivity of Epstein-Barr virus (EBV)-positive lymphoma cells to ganciclovir [28]. The gene discussed is HDAC9; the disease is lymphoma.